Imetelstat Sodium

Summary

Imetelstat Sodium (CHEMBL2108702) is an approved unknown; indicated across 5 conditions including anemia and breast neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108702
Name	Imetelstat Sodium
Type	Unknown
Max phase	4

Also known as: GRN-163L TRIDECASODIUM SALT, GRN163L, GRN163L TRIDECASODIUM SALT, Imetelstat sodium, Rytelo, IMETELSTAT SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anemia	4	MONDO:0002280	MONDO:0002280
breast neoplasm	2	MONDO:0021100	MONDO:0007254
neoplasm	1	MONDO:0005070	EFO:0000616
plasma cell myeloma	1	MONDO:0009693	EFO:0001378
lung neoplasm	1	MONDO:0021117	MONDO:0008903

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02598661	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT05583552	PHASE2	ACTIVE_NOT_RECRUITING	Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
NCT01256762	PHASE2	COMPLETED	Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
NCT01836549	PHASE2	TERMINATED	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
NCT02011126	PHASE2	WITHDRAWN	Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
NCT05371964	PHASE1	RECRUITING	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
NCT00124189	PHASE1	COMPLETED	Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
NCT00732056	PHASE1	COMPLETED	A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
NCT01273090	PHASE1	COMPLETED	Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).